Skip to main content

Need urgent help? Start triage first, then route to emergency care.

Meds A-Z

Prednisolone

Detailed information about Prednisolone

Official label facts Owner quick guide first Marketing clearly labeled
Showing simplified owner view. Switch to Vet View for full technical detail.

Pet Owner Quick Guide

Start here: what this medicine is for, what it does, and when it's usually needed.

Usually used for:

Antipruritic : Trimeprazine with Prednisolone is recommended for the relief of itching regardless of cause. Its usefulness has been demonstrated for the relief of itching and the reduction of inflammation commonly associ...

What it does:

The drug is indicated in the treatment of dogs for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylit...

When it's needed:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinica...

Call your vet sooner if you notice:

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered late in pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Commonly reported reactions:

  • (2 reports)
  • (2 reports)
  • (1 reports)

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Talk to a Vet / Find a Vet Near You
Image coming soon
Prednisolone

Prednisolone

Drug type: Generic ingredient • Branded profile FDA branded products available

Species: Both

Manufacturer: Zoetis Inc.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Zoetis Inc.
Form: Capsule, Liquid, Liquid (Solution), Liquid (Suspension), Ointment, Tablet
Identifiers:
ANADA: 200784 NADA: 10312 NADA: 11080 NADA: 11403 NADA: 11437 NADA: 11593 NADA: 11700 NADA: 11703 NADA: 117973 NADA: 12204 NADA: 12437 NADA: 12444 NADA: 135771 NADA: 136212 NADA: 140921 NADA: 141298 NADA: 32322 NADA: 35161 NADA: 45288 NADA: 55005
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered late in pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered late in pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
10
Species represented
2
Most Reported Reactions
Reaction Cases Species Serious cases
2 Cat, Dog 1
2 Cat, Dog 0
1 Cat 1
1 Cat 1
1 Cat 1
1 Cat 1
1 Cat 1
1 Cat 1

Species coverage: Dog (18) Cat (14)

View detailed reaction table
Reaction Species Seriousness Frequency Reports
Dog Non-serious - 1
Dog Non-serious - 1
Cat Serious - 1
Dog Non-serious - 1
Dog Serious - 1
Cat Serious - 1
Cat Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Cat Serious - 1
Cat Serious - 1
Cat Serious - 1
Cat Non-serious - 1
Dog Non-serious - 1
Cat Non-serious - 1
Cat Serious - 1
Cat Non-serious - 1
Cat Non-serious - 1
Dog Non-serious - 1
Cat Serious - 1
Cat Serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Cat Serious - 1
Dog Non-serious - 1
Source metadata:

Storage & Handling

No storage/handling guidance is linked yet.

Source metadata: No source yet.

Documents

Official label facts are separated from secondary summaries.

Official documents: 30 • Secondary summaries: 0

Secondary summaries

No source yet.

Promotional Materials (Marketing)

This content is marketing material and not clinical guidance.

No marketing assets are linked yet.

No source yet.

Source metadata: No source yet.
Talk to a Vet / Find a Vet Near You
Technical appendix (vet reference)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:03 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 12, 2026, 10:43 PM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Chlorasone Ophthalmic Ointment Cortaba® Tablets Delta Albaplex® 3x Tablets Delta Albaplex® Tablets Depo-Medrol® Hydeltrone Ointment Hydeltrone-TBA Suspension Liquichlor with Cerumene Liquisone F with Cerumene Medrol® Tablets Methylprednisolene Tablets Methylprednisolone Acetate Inj. Meticortelone Acetate Neo-Delta Cortef® Sterile Solution Neo-Delta-Cortef® with Tetracaine Ointment Optisone Prednis-A-Vet Injection PrednisTab® Prednisolone Aqueous Suspension Prednisolone Sodium Succinate for Injection Solu-Delta Cortef® Sterile Powder Surolan® Temaril-P® Spansule Capsule No. 2 Temaril-P® Spansule Capsule No. 1 Temaril-P® Tablets Trimeprazine with Prednisolone
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Cat, Dog, Horse, Restricted During Pregnancy
Rx/OTC: RX
Form/route: Capsule, Liquid, Liquid (Solution), Liquid (Suspension), Ointment, Tablet Intra-Articular, Intramuscular, Intrasynovial, Intravenous, Ophthalmic, Oral, Otic, Topical
Applications: ANADA 200-784 • NADA 11403 • NADA 135-771 • NADA 12437 • NADA 11437 • NADA 11080 • NADA 12204 • NADA 98288 • NADA 136-212 • NADA 140-921 • NADA 65259 • NADA 11700 • NADA 65090 • NADA 55005 • NADA 32322 • NADA 10312 • NADA 91534 • NADA 11703 • NADA 45288 • NADA 12444 • NADA 117-973 • NADA 11593 • NADA 141-298 • NADA 35161
NDC: Packages 11695-7043-1 11695-7043-2 86117-032-07 86117-032-13 Products 11695 11695 86117 86117
Documents: 4 (FOI: 4) • SPL: 26 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 56 Cat 56 View
Case summaries: 11 (showing 8) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes
ICD10_CM: E11.9 ICD10_CM: H60.90 ICD10_CM: J20.9
Type 2 diabetes mellitus without complications

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered late in pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Behavioural disorder NOS (1) Bumps on skin (1) Cardiac arrest (1) Cyanotic spots/blotchy skin (1) Deafness (1) Death (1) Decreased appetite (1) Decreased appetite (1) Diarrhoea (1) Erythema (for urticaria see Immune SOC) (1) Eye irritation (1) Facial pruritus (1) Food refusal (1) Haemorrhage NOS (1) Hard stool (1) Hives (see also Skin) (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200784 NADA: 10312 NADA: 11080 NADA: 11403 NADA: 11437 NADA: 11593 NADA: 11700 NADA: 11703 NADA: 117973 NADA: 12204 NADA: 12437 NADA: 12444 NADA: 135771 NADA: 136212 NADA: 140921 NADA: 141298 NADA: 32322 NADA: 35161 NADA: 45288 NADA: 55005 NADA: 65090 NADA: 65259 NADA: 91534 NADA: 98288
Package NDC Product NDC Form / Route Status
11695-4469-1 11695 -
11695-4470-1 11695 -
11695-7043-1 11695 -
11695-7043-2 11695 -
11789-248-10 11789 -
11789-249-10 11789 -
50989-163-53 50989 -
50989-286-52 50989 -
54771-1613-1 54771 -
54771-1614-1 54771 -
54771-3547-1 54771 -
54771-8550-1 54771 -
54771-8550-2 54771 -
57319-441-16 57319 -
58198-0813-1 58198 -
58198-0813-2 58198 -
62157-152-01 62157 -
62157-413-01 62157 -
62157-414-01 62157 -
69043-042-10 69043 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Revision History

Every non-trivial field is expected to include provenance and update timestamps.

Official 7 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food. Federal law restricts this drug … (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Loss of hearing, Vomiting, Deafness, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurolo… (Official, 2026-02-12)
  • usage: The drug is indicated in the treatment of dogs for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoske… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Trimeprazine with Prednisolone
RX
Prednisolone Trimeprazine Tartrate
Tablet Oral
ZYVET AH, Inc. ANADA 200-784 Approved Jul 1, 2024
Medrol® Tablets
RX
Methylprednisolone
Tablet Oral
Zoetis Inc. NADA 11403 Approved Feb 23, 2024
Methylprednisolene Tablets
RX
Methylprednisolone
Tablet Oral
Cronus Pharma Specialities India Private Ltd. NADA 135-771 Approved Nov 24, 2023
Temaril-P® Tablets
RX
Prednisolone Trimeprazine Tartrate
Tablet Oral
Zoetis Inc. NADA 12437 Approved Jun 7, 2023
Hydeltrone Ointment
RX
Neomycin Sulfate Prednisolone Sodium Phosphate
Ointment Ophthalmic, Topical
Boehringer lngelheim Animal Health USA Inc. NADA 11437 W May 3, 2023
Hydeltrone-TBA Suspension
RX
Prednisolone Tertiary Butylacetate
Liquid (Suspension) Intrasynovial, Intramuscular
Boehringer lngelheim Animal Health USA Inc. NADA 11080 W May 3, 2023
Depo-Medrol®
RX
Methylprednisolone Acetate
Liquid (Suspension) Intramuscular, Intrasynovial
Zoetis Inc. NADA 12204 Approved Dec 7, 2021
Prednis-A-Vet Injection
RX
Prednisolone Sodium Phosphate
Liquid (Solution) Intravenous
Bimeda Animal Health Limited NADA 98288 Approved Oct 2, 2018
Methylprednisolone Acetate Inj.
RX
Methylprednisolone Acetate
Liquid (Suspension) Intramuscular, Intrasynovial
Cronus Pharma Specialities India Private Ltd. NADA 136-212 Approved Feb 1, 2018
PrednisTab®
RX
Prednisolone
Tablet Oral
Lloyd, Inc. NADA 140-921 Approved May 17, 2017
Chlorasone Ophthalmic Ointment
RX
Chloramphenicol Prednisolone Acetate
Ointment Ophthalmic
Evsco Pharmaceuticals, An Affiliate of IGI, Inc. NADA 65259 W Jun 1, 2016
Cortaba® Tablets
RX
Acetylsalicylic Acid Methylprednisolone
Tablet Oral
Zoetis Inc. NADA 11700 Approved Jun 1, 2016
Delta Albaplex® 3x Tablets Delta Albaplex® Tablets
RX
Novobiocin Sodium Prednisolone Tetracycline Hydrochloride
Tablet Oral
Zoetis Inc. NADA 65090 Approved Jun 1, 2016
Liquichlor with Cerumene
RX
Chloramphenicol Prednisolone Squalene Tetracaine
Evsco Pharmaceuticals, An Affiliate of IGI, Inc. NADA 55005 W Jun 1, 2016
Liquisone F with Cerumene
RX
Hexamethyltetracosane Neomycin Sulfate Prednisolone Tetracaine
Liquid (Suspension) Topical
Evsco Pharmaceuticals, An Affiliate of IGI, Inc. NADA 32322 W Jun 1, 2016
Meticortelone Acetate
RX
Prednisolone Acetate
Liquid (Suspension) Intramuscular, Intra-Articular
Intervet, Inc. NADA 10312 Approved Jun 1, 2016
Neo-Delta Cortef® Sterile Solution
RX
Neomycin Sulfate Prednisolone Acetate
Liquid (Suspension) Ophthalmic
Zoetis Inc. NADA 91534 Approved Jun 1, 2016
Neo-Delta-Cortef® with Tetracaine Ointment
RX
Neomycin Sulfate Prednisolone Acetate Tetracaine Hydrochloride
Liquid (Suspension) Ophthalmic
Zoetis Inc. NADA 11703 Approved Jun 1, 2016
Optisone
RX
Neomycin Sulfate Prednisolone Acetate
Ointment Ophthalmic
Evsco Pharmaceuticals, An Affiliate of IGI, Inc. NADA 45288 W Jun 1, 2016
Prednisolone Aqueous Suspension
RX
Prednisolone Acetate
Akorn, Inc. NADA 12444 W Jun 1, 2016
Prednisolone Sodium Succinate for Injection
RX
Prednisolone Sodium Succinate
Watson Laboratories, Inc. NADA 117-973 W Jun 1, 2016
Solu-Delta Cortef® Sterile Powder
RX
Prednisolone Sodium Succinate
Liquid Intravenous, Intramuscular
Zoetis Inc. NADA 11593 Approved Jun 1, 2016
Surolan®
RX
Miconazole Nitrate Polymyxin B Sulfate Prednisolone Acetate
Liquid (Suspension) Otic
Elanco US Inc. NADA 141-298 Approved Jun 1, 2016
Temaril-P® Spansule Capsule No. 2 Temaril-P® Spansule Capsule No. 1
RX
Prednisolone Trimeprazine Tartrate
Capsule Oral
Zoetis Inc. NADA 35161 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
Each tablet contains 5 mg trimeprazine as trimeprazine tartrate and 2 mg prednisolone.
Dogs
Indication

Antipruritic: Trimeprazine with Prednisolone is recommended for the relief of itching regardless of cause. Its usefulness has been demonstrated for the relief of itching and the reduction of inflammation commonly associated with most skin disorders of dogs such as the eczema caused by internal disorders, otitis, and dermatitis (allergic, parasitic, pustular, and nonspecific). It often relieves pruritis which does not respond to other therapy.

Antitussive: Trimeprazine with Prednisolone has been found to be effective therapy and adjunctive therapy in various cough conditions of dogs. Therefore, in addition to its antipruritic action, Trimeprazine with Prednisolone is recommended for the treatment of “kennel cough” or tracheobronchitis, bronchitis including all allergic bronchitis, and infections and coughs of nonspecific origin. (Coughs due to cardiac insufficiency would not be expected to respond to Trimeprazine with Prednisolone therapy).

Dosage

The drug is administered orally at an initial dosage level of 1/2 tablet twice daily to dogs weighing up to 10 pounds, one tablet twice daily to dogs weighing 11 to 20 pounds, two tablets twice daily to dogs weighing 21 to 40 pounds, and three tablets twice daily to dogs weighing over 40 pounds. After 4 days, the dosage is reduced to approximately 1/2 the initial dosage or to an amount just sufficient to maintain remission of symptoms. Dosages in individual cases may vary and should be adjusted until proper response is obtained.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy • Cat, Restricted During Pregnancy
Composition / specifications
Each tablet contains 1 or 4 milligrams of methylprednisolone.
Dogs
Indication
For use in dogs as an anti-inflammatory agent.
Dosage
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.
Limitations
Cats
Indication
For use in cats as an anti-inflammatory agent.
Dosage
5 to 15 pounds, 2 milligrams; 15 to 40 pounds, 2 to 4 milligrams; 40 to 80 pounds, 4 to 8 milligrams.
Limitations
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in dogs and cats but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy • Cat, Restricted During Pregnancy
Composition / specifications
Each tablet contains 1, 2 or 4 milligrams of methylprednisolone.
Dogs
Indication
For use as an anti-inflammatory agent.
Dosage
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.
Limitations
Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, cushingoid syndrome. The presence of active tuberculosis diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.
Cats
Indication
For use as an anti-inflammatory agent.
Dosage
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. 5 to 15 pounds: 2 milligrams; 15 to 40 pounds: 2 to 4 milligrams; 40 to 80 pounds: 4 to 8 milligrams.
Limitations

Hazardous for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, corneal ulcer, and cushingoid syndrome. The presence of diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs and cats but should be kept in mind. Antiinflammatory action of corticosteroids may mask signs of infection.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy
Composition / specifications
Each tablet contains 5 milligrams trimeprazine tartrate and 2 milligrams prednisolone.
Dogs
Indication

The drug is administered orally to dogs for the relief of itching regardless of cause; reduction of inflammation commonly associated with most skin disorders of dogs such as eczema, caused by internal disorders, otitis, and dermatitis, (allergic, parasitic, pustular, and nonspecific). It is also used in dogs as adjunctive therapy in various cough conditions including treatment of “kennel cough” or tracheobronchitis, bronchitis including allergic bronchitis, infections and coughs of nonspecific origin. The product may also be administered to dogs suffering from acute or chronic bacterial infections provided the infection is controlled by appropriate antibiotic or chemotherapeutic agents.

Dosage
The drug is administered orally at an initial dosage level of 1/2 tablet twice daily to dogs weighing up to 10 pounds, one tablet twice daily to dogs weighing 11 to 20 pounds, two tablets twice daily to dogs weighing 21 to 40 pounds, and three tablets twice daily to dogs weighing over 40 pounds. After 4 days, the dosage is reduced to approximately 1/2 the initial dosage or to an amount just sufficient to maintain remission of symptoms. Dosages in individual cases may vary and should be adjusted until proper response is obtained.
Limitations

Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Prednisolone sodium phosphate-neomycin sulfate ophthalmic ointment contains prednisolone sodium phosphate equivalent to 2.5 milligrams prednisolone 21-phosphate and 5 milligrams neomycin sulfate (equivalent to 3.5 milligrams neomycin base) in each gram of ointment.
Cats
Indication
The drug is recommended for use in superficial ocular inflammations or infections limited to the conjunctiva or the anterior segment of the eye of cats, such as those associated with allergic reactions or gross irritants.
Dosage
A small quantity of the ointment should be expressed into the conjunctival sac 4 times a day (at intervals of 1 to 8 hours) for a few days until there is a favorable response, then the frequency of application may be reduced to twice daily as long as the condition remains under control. Treatment may require from a few days to several weeks.
Limitations
All topical ophthalmic preparations containing corticosteroids with or without an antimicrobial agent are contraindicated in the initial treatment of corneal ulcers. They should not be used until the infection is under control and corneal regeneration is well underway. For use only by or on the order of a licensed veterinarian.
Dogs
Indication
The drug is recommended for use in superficial ocular inflammations or infections limited to the conjunctiva or the anterior segment of the eye of dogs, such as those associated with allergic reactions or gross irritants.
Dosage
A small quantity of the ointment should be expressed into the conjunctival sac 4 times a day (at intervals of 1 to 8 hours) for a few days until there is a favorable response, then the frequency of application may be reduced to twice daily as long as the condition remains under control. Treatment may require from a few days to several weeks.
Limitations
All topical ophthalmic preparations containing corticosteroids with or without an antimicrobial agent are contraindicated in the initial treatment of corneal ulcers. They should not be used until the infection is under control and corneal regeneration is well underway. For use only by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy • Horse, Restricted During Pregnancy • Cat, Restricted During Pregnancy
Composition / specifications
Prednisolone tertiary butylacetate suspension contains 20 milligrams of prednisolone tertiary butylacetate per milliliter. It is sterile.
Horses
Indication
It is used as an anti-inflammatory agent in horses.
Dosage
It is administered to horses intramuscularly at a dosage level of 100 to 300 milligrams and intrasynovially at a dosage level of 50 to 100 milligrams. Intramuscular re-treatment of horses in 24 to 48 hours may be necessary, depending on the general condition of the animal and the severity and duration of the disease.
Limitations
Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered late in pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication
It is used as an anti-inflammatory agent in cats.
Dosage
It is administered intramuscularly to cats at a dosage level of 1 milligram per 5 pounds of body weight and intrasynovially at a dosage level of 10 to 20 milligrams.
Limitations
Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered late in pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Dogs
Indication
It is used as an anti-inflammatory agent in dogs.
Dosage
It is administered intramuscularly to dogs at a dosage level of 1 milligram per 5 pounds of body weight and intrasynovially at a dosage level of 10 to 20 milligrams.
Limitations
Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered late in pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy • Restricted During Pregnancy • Cat, Restricted During Pregnancy
Composition / specifications
Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.
Dogs
Indication
Treatment of inflammation and related disorders in dogs; treatment of allergic and dermatologic disorders in dogs; and as supportive therapy to antibacterial treatment of severe infections in dogs.
Dosage
2 to 40 milligrams (up to 120 milligrams in extremely large breeds or dogs with severe involvement) intramuscularly. Dosage may be repeated when necessary. Up to 20 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Cats
Indication
Treatment of inflammation and related disorders in cats; treatment of allergic and dermatologic disorders in cats; and as supportive therapy to antibacterial treatment of severe infections in cats.
Dosage
10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.
Limitations

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

Horses
Indication
Treatment of inflammation and related disorders in horses.
Dosage
200 milligrams intramuscularly. Dosage may be repeated when necessary. 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations

Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy
Composition / specifications
Each milliliter contains 20 milligrams of prednisolone sodium phosphate (equivalent to 14.88 milligrams of prednisolone) in sterile aqueous solution.
Dogs
Indication
It is used in treatment of dogs when a rapid adrenal glucocorticoid and/or anti-inflammatory effect is necessary.
Dosage
It is administered intravenously in a dosage of 2 1/2 to 5 milligrams of prednisolone sodium phosphate per pound of body weight, initially for shock and shock-like states, followed by equal maintenance doses at 1-, 3-, 6-, or 10-hour intervals as determined by the condition of the animal. If permanent use is required, oral therapy (tablets) may be substituted. If therapy is to be withdrawn after prolonged use, reduce daily dose gradually over a number of days.
Limitations
Do not use in viral infections. Except in emergency therapy, do not use with tuberculosis, chronic nephritis, Cushing's disease, or peptic ulcers. With infections, use appropriate antibacterial therapy with and for at least 3 days after, discontinuance of use and disappearance of all signs of infection. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy • Horse, Restricted During Pregnancy • Horse, Not For Meat Production • Cat, Restricted During Pregnancy
Composition / specifications
Each milliliter of aqueous suspension contains 20 or 40 milligrams of methylprednisolone acetate.
Dogs
Indication
Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.
Dosage
2 to 40 milligrams (up to 120 milligrams in extremely large breeds or dogs with severe involvement) intramuscularly. Dosage may be repeated when necessary. Or up to 20 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations
Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.
Cats
Indication
Treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.
Dosage
10 to 20 milligrams intramuscularly. Dosage may be repeated when necessary.
Limitations
Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.
Horses
Indication
Treatment of inflammation and related disorders.
Dosage
200 milligrams intramuscularly. Dosage may be repeated when necessary. Or 40 to 240 milligrams intrasynovially. Dosage may be repeated when necessary.
Limitations
Not for use in horses intended for food. Not for human use. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing's syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy
Composition / specifications
Each tablet contains 5 or 20 milligrams prednisolone.
Dogs
Indication
For use as an anti-inflammatory agent.
Dosage
2.5 milligrams per 10 pounds (4.5 kg) body weight per day.
Limitations
Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate parturition followed by dystocia, fetal death, retained placenta, and metritis. Do not use in viral infections. Systemic therapy with prednisolone is contraindicated in animals with peptic ulcer, corneal ulcer, and Cushingoid syndrome. The presence of diabetes, osteoporosis, predisposition to thrombophlebitis hypertension, congestive heart failure, renal insufficiency and active tuberculosis necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs but should be kept in mind. Anti-inflammatory action of corticosteroids may mask signs of infection.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each gram of the product contains 10 milligrams of chloramphenicol and 2.5 milligrams of prednisolone acetate.
Dogs
Indication
Treatment of bacterial conjunctivitis and ocular inflammation caused by organisms susceptible to chloramphenicol.
Dosage
4 to 6 times daily to the affected eye for the first 72 hours depending upon the severity of the condition. Continue treatment for 48 hours after the eye appears normal.
Limitations
For use only by or on the order of a licensed veterinarian.
Cats
Indication
Treatment of bacterial conjunctivitis and ocular inflammation caused by organisms susceptible to chloramphenicol.
Dosage
4 to 6 times daily to the affected eye for the first 72 hours depending upon the severity of the condition. Continue treatment for 48 hours after the eye appears normal.
Limitations
For use only by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy
Composition / specifications
Each tablet contains 0.5 milligram of methylprednisolone and 300 milligrams of aspirin.
Dogs
Indication
As an anti-inflammatory and analgesic agent in dogs.
Dosage
Dogs under 15 pounds, 1/4 to 1 tablet daily; 15 to 60 pounds, 1 to 2 tablets daily; 60 pounds and over, 2 tablets daily.
Limitations
Administer total daily dose in divided doses 6 to 10 hours apart, with a light feeding. When response is attained, dosage should be gradually reduced until maintenance level is achieved. Do not administer to cats. Do not overdose. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Systemic therapy with methylprednisolone is contraindicated in animals with tuberculosis, chronic nephritis, peptic ulcer, or Cushingoid syndrome. The presence of diabetes mellitus, osteoporosis predisposition to thrombophlebitis, hypertension, congestive heart failure, or renal insufficiency necessitates carefully controlled use of corticosteroids. Anti-inflammatory action of corticosteroids may mask signs of infection.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy
Composition / specifications
Each tablet contains the equivalent of 180 milligrams of tetracycline hydrochloride, 180 milligrams of novobiocin, and 4.5 milligrams of prednisolone.
Label highlights
Indication
Treatment of acute and chronic canine infections such as tonsillitis, bronchitis, and tracheobronchitis when caused by pathogens susceptible to tetracycline and/or novobiocin, such as Staphylococcus species and Escherichia coli, when it is necessary to initially reduce the severity of associated clinical signs.
Dosage
Ten milligrams of each antibiotic and 0.25 milligram of prednisolone per pound of body weight (1 tablet for each 18 pounds) every 12 hours for 48 hours. Treatment is to be continued with novobiocin and tetracycline alone at the same dose schedule for an additional 3 days or longer as needed.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of suspension contains 5 milligrams neomycin sulfate (equivalent to 3.5 milligrams neomycin base), 2 milligrams prednisolone, 5 milligrams tetracaine, and 0.25 milliliter squalane (hexamethyltetracosane).
Dogs
Indication
For treating acute otitis externa and as adjunctive therapy in management of chronic otitis externa. Also for treating moist dermatitis in dogs.
Dosage
2 to 3 applications daily or as needed.
Limitations
Tetracaine and neomycin have the potential to sensitize. If signs of irritation or sensitivity develop, discontinue use. Prolonged use of this product may result in overgrowth of non-susceptible organisms. If new infections due to bacteria or fungi appear during therapy, appropriate measures should be taken. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication
For treating acute otitis externa and as adjunctive therapy in management of chronic otitis externa.
Dosage
2 to 3 applications daily or as needed.
Limitations
Tetracaine and neomycin have the potential to sensitize. If signs of irritation or sensitivity develop, discontinue use. Prolonged use of this product may result in overgrowth of non-susceptible organisms. If new infections due to bacteria or fungi appear during therapy, appropriate measures should be taken. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Horse, Not For Meat Production • Cat, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of sterile aqueous suspension contains 25 milligrams of prednisolone acetate.
Dogs
Indication
The drug is indicated in the treatment of dogs for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and post-operatively and for various stress conditions when corticosteroids are required while the animal is being treated for a specific condition.
Dosage
The drug is administered to dogs intramuscularly at a dosage level of 10 to 50 milligrams. The dosage may be repeated when necessary. If the condition is of a chronic nature, an oral corticosteroid may be given as a maintenance dosage. The drug may be given intra-articularly to dogs at a dosage level of 5 to 25 milligrams. The dose may be repeated when necessary after 7 days for two or three doses.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication
The drug is indicated in the treatment of cats for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and post-operatively and for various stress conditions when corticosteroids are required while the animal is being treated for a specific condition.
Dosage
The drug is administered to cats intramuscularly at a dosage level of 10 to 50 milligrams. The dosage may be repeated when necessary. If the condition is of a chronic nature, an oral corticosteroid may be given as a maintenance dosage. The drug may be given intra-articularly to cats at a dosage level of 5 to 25 milligrams. The dose may be repeated when necessary after 7 days for two or three doses.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Horses
Indication
The drug is indicated in the treatment of horses for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and post-operatively and for various stress conditions when corticosteroids are required while the animal is being treated for a specific condition.
Dosage
The drug is administered to horses intra-articularly at a dosage level of 50 to 100 milligrams. The dose may be repeated when necessary. If no response is noted after 3 or 4 days, the possibility must be considered that the condition is unresponsive to prednisolone therapy.
Limitations
Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Prednisolone acetate-neomycin sulfate sterile suspension contains 2.5 milligrams of prednisolone acetate and 5 milligrams of neomycin sulfate (equivalent to 3.5 milligrams of neomycin base) in each milliliter of sterile suspension
Dogs
Indication
The drug is indicated for treating infectious allergic and traumatic keratitis and conjunctivitis, otitis externa, and chronic otitis externa in dogs.
Dosage
For beginning treatment of acute ocular inflammations 1 or 2 drops may be placed in the conjunctival sac 3 to 6 times during a 24 hour period. When improvement occurs, the dosage may be reduced to 1 drop 2 to 4 times daily. In otitis externa, 2 to 6 drops may be placed in the external ear canal 2 or 3 times daily.
Limitations
All topical ophthalmic preparations containing corticosteroids with or without an anti-microbial agent are contraindicated in the initial treatment of corneal ulcers. They should not be used until infection is under control and corneal regeneration is well underway. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication
The drug is indicated for treating infectious allergic and traumatic keratitis and conjunctivitis, otitis externa, and chronic otitis externa in cats.
Dosage
For beginning treatment of acute ocular inflammations 1 or 2 drops may be placed in the conjunctival sac 3 to 6 times during a 24 hour period. When improvement occurs, the dosage may be reduced to 1 drop 2 to 4 times daily. In otitis externa, 2 to 6 drops may be placed in the external ear canal 2 or 3 times daily.
Limitations
All topical ophthalmic preparations containing corticosteroids with or without an anti-microbial agent are contraindicated in the initial treatment of corneal ulcers. They should not be used until infection is under control and corneal regeneration is well underway. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Horse, Not For Meat Production • Cat, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of prednisolone sodium succinate injection contains: Prednisolone sodium succinate equivalent in activity to 10, 20, or 50 milligrams of prednisolone.
Horses
Indication
The drug is intended for the treatment of horses.
Dosage
The dosage for horses is 50 to 100 milligrams as an initial dose given intravenously over a period of one-half to 1 minute, or intramuscularly and may be repeated in inflammatory, allergic, or other stress conditions at intervals of 12, 24, or 48 hours, depending upon the size of the animal, the severity of the condition and the response to treatment.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Dogs
Indication
The drug is intended for the treatment of inflammatory, allergic and less severe stress conditions, where immediate effect is not required, in dogs.
Dosage
The drug may be given intramuscularly at 1 to 5 milligrams ranging upward to 30 to 50 milligrams in large breeds of dogs. Dosage may be repeated in 12 to 24 hours and continued for 3 to 5 days if necessary. If permanent corticosteroid effect is required oral therapy with prednisolone tablets may be substituted.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Indication
The drug is intended for treatment of shock in dogs.
Dosage
The drug is administered intravenously at a range of 2.5 to 5 milligrams per pound of body weight as an initial dose followed by maintenance doses at 1, 3, 6, or 10 hour intervals, as determined by the condition of the animal.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication
The drug is intended for the treatment of inflammatory, allergic and less severe stress conditions, where immediate effect is not required, in cats.
Dosage
The drug may be given intramuscularly at 1 to 5 milligrams ranging upward to 30 to 50 milligrams in large breeds of dogs. Dosage may be repeated in 12 to 24 hours and continued for 3 to 5 days if necessary. If permanent corticosteroid effect is required oral therapy with prednisolone tablets may be substituted.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
23 mg/mL miconazole nitrate, 0.5293 mg/mL polymyxin B sulfate, 5 mg/mL prednisolone acetate
Dogs
Indication
For the treatment of canine otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).
Dosage
Instill 5 drops in the ear canal twice daily and massage the ear. Therapy should continue for 7 consecutive days.
Limitations
For otic use in dogs only. Do not administer orally. Do not use in dogs with known perforated tympanum. Do not use with drugs known to induce ototoxicity. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Restricted During Pregnancy
Composition / specifications
Each capsule contains 3.75 milligrams of trimeprazine in sustained released form (as the tartrate) and 1 milligram of prednisolone.
Dogs
Indication
For the relief of itching regardless of cause reduction of inflammation commonly associated with most skin disorders of dogs such as eczema caused by internal disorders, otitis, and dermatitis (allergic, parasitic, pustular and nonspecific). It is also used in dogs as adjunctive therapy in various cough conditions including treatment of "kennel cough" or tracheobronchitis, bronchitis including allergic bronchitis, tonsillitis, acute upper respiratory infections, and coughs of nonspecific origin. The product may also be administered to dogs suffering from acute or chronic bacterial infections, provided the infection is controlled by appropriate antibiotic or chemotherapeutic agents.
Dosage
Up to 10 pounds body weight- 1 capsule orally once daily. 11 to 20 pounds body weight- 2 capsules orally once daily. 21 to 40 pounds body weight- 4 capsules orally once daily. Over 40 pounds body weight- 6 capsules orally once daily.
Limitations
After 4 days, reduce dosage to one-half the initial dose or to an amount sufficient to maintain remission of symptoms. Dosages in individual cases may vary and should be adjusted until proper response is obtained. Do not use the drug in cases of viral infections involving corneal ulceration or dendritic ulceration of the cornea. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary

    Antipruritic: Trimeprazine with Prednisolone is recommended for the relief of itching regardless of cause. Its usefulness has been demonstrated for the relief of itching and the reduction of inflammation commonly associated with most skin disorders of dogs such as the eczema caused by internal disorders, otitis, and dermatitis (allergic, parasitic, pustular, and nonspecific). It often relieves pruritis which does not respond to other therapy.

    Antitussive: Trimeprazine with Prednisolone has been found to be effective therapy and adjunctive therapy in various cough conditions of dogs. Therefore, in addition to its antipruritic action, Trimeprazine with Prednisolone is recommended for the treatment of "kennel cough" or tracheobronchitis, bronchitis including all allergic bronchitis, and infections and coughs of nonspecific origin. (Coughs due to cardiac insufficiency would not be expected to respond to Trimeprazine with Prednisolone therapy).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

SPL Packages

FDA page: Open in Animal Drugs @ FDA

SPL Packages

FDA page: Open in Animal Drugs @ FDA

SPL Packages

FDA page: Open in Animal Drugs @ FDA

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    Provides for a new 20 mg tablet size.

  • Summary
    PrednisTab™ is intended for use in dogs. The indications for PrednisTab™ are the same as those for other anti-inflammatory steroids and comprise the various collagen, dermal, allergic, ocular, otic, and musculoskeletal conditions known to be responsive to the anti-inflammatory corticosteroids.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

SPL Packages

FDA page: Open in Animal Drugs @ FDA

SPL Packages

FDA page: Open in Animal Drugs @ FDA

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    For the treatment of canine otitis externa associated with susceptible strains of yeast ( Malassezia pachydermatis) and bacteria ( Staphylococcus pseudintermedius)
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

The drug is indicated in the treatment of dogs for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and post-operatively and for various stress conditions when corticosteroids are required while the animal is being treated for a specific condition. The drug is indicated in the treatment of cats for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and post-operatively and for various stress conditions when corticosteroids are required while the animal is being treated for a specific condition. The drug is indicated in the treatment of horses for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and post-operatively and for various stress conditions when corticosteroids are required while the animal is being treated for a specific condition.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered late in pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

No approved side-effect narrative is linked yet.

openFDA reaction signals are available for Dog 56 and Cat 56 (view top reported reactions).

Top Reported Reactions (openFDA)

Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).

Dog
Digestive
Vomiting (163) Diarrhea (92) Loss of appetite (71) Diarrhea (4) Diarrhea (4) Diarrhea (4) Diarrhea (4) Diarrhea (4) Diarrhea (4) Loss of appetite (4) Loss of appetite (4) Loss of appetite (4) Loss of appetite (4) Loss of appetite (4) Loss of appetite (4) Vomiting (3) Vomiting (3) Vomiting (3) Vomiting (3) Vomiting (3) Vomiting (3)
Skin & allergy
Hives (3) Hives (3) Hives (3) Hives (3) Hives (3) Hives (3)
Neurologic
Tiredness (lethargy) (111) Tiredness (lethargy) (6) Tiredness (lethargy) (6) Tiredness (lethargy) (6) Tiredness (lethargy) (6) Tiredness (lethargy) (5) Tiredness (lethargy) (5) Unsteady walking (ataxia) (3) Unsteady walking (ataxia) (3) Unsteady walking (ataxia) (3) Unsteady walking (ataxia) (3) Unsteady walking (ataxia) (3) Unsteady walking (ataxia) (3)
Effectiveness
Lack of efficacy - NOS (138)
Other
Loss of hearing (184) Deafness (144) Impaired hearing (76) Other abnormal test result NOS (3) Other abnormal test result NOS (3) Other abnormal test result NOS (3) Other abnormal test result NOS (3) Other abnormal test result NOS (3) Other abnormal test result NOS (3) Shaking (3) Shaking (3) Shaking (3) Shaking (3) Shaking (3) Shaking (3)
Cat
Digestive
Vomiting (133) Loss of appetite (80) Decreased appetite (2) Decreased appetite (2) Decreased appetite (2) Decreased appetite (2) Decreased appetite (2) Decreased appetite (2) Vomiting (2) Vomiting (2) Vomiting (2) Vomiting (2) Vomiting (2) Vomiting (2)
Neurologic
Tiredness (lethargy) (84) Tiredness (lethargy) (79) Tiredness (lethargy) (2) Tiredness (lethargy) (2) Tiredness (lethargy) (2) Tiredness (lethargy) (2) Tiredness (lethargy) (2) Tiredness (lethargy) (2) Unsteady walking (ataxia) (2) Unsteady walking (ataxia) (2) Unsteady walking (ataxia) (2) Unsteady walking (ataxia) (2) Unsteady walking (ataxia) (2)
Effectiveness
Lack of efficacy - NOS (108) Lack of efficacy - NOS (3) Lack of efficacy - NOS (3) Lack of efficacy - NOS (3) Lack of efficacy - NOS (3) Lack of efficacy - NOS (2) Lack of efficacy - NOS (2)
Other
Weight loss (101) Death by euthanasia (82) Not eating (75) Weight loss (4) Weight loss (4) Weight loss (4) Weight loss (4) Medication error NOS (2) Medication error NOS (2) Medication error NOS (2) Medication error NOS (2) Medication error NOS (2) Medication error NOS (2) Vocalisation (2) Vocalisation (2) Vocalisation (2) Vocalisation (2) Vocalisation (2) Vocalisation (2) Weight loss (2) Weight loss (2) Abnormal cytology (1)

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Lhasa Apso, Female, 10.92 year, 11.16 kilogram • Drug: MSK, Unknown • Reactions: Diarrhea, Oral mass • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-056010
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 10.92 Year
  • Weight: 11.160 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Diarrhea Oral mass
Outcomes: Ongoing

Dog, ['Retriever - Golden', 'Poodle (unspecified)'], Male, 3 year, 31.75 kilogram • Drug: MSK, Suspension, Intraocular • Reactions: Squinting, Eye irritation, Medication error NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055998
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 3.00 Year
  • Weight: 31.750 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intraocular
  • Form: Suspension
Reactions Reported:
Squinting Eye irritation Medication error NOS
Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 12 year, 10.43 kilogram • Drug: MSK, Unknown • Reactions: Weight loss, Vomiting, Decreased appetite, Hard stool • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055784
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 10.430 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Weight loss Vomiting Decreased appetite Hard stool
Outcomes: Outcome Unknown

Cat, Domestic Longhair, Male, 15 year, 4.19 kilogram • Drug: MSK, Unknown • Reactions: Vomiting • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-056003
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 4.190 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Vomiting
Outcomes: Outcome Unknown

Dog, Shih Tzu, Female, 13 year, 6.623 kilogram • Drug: MSK, Oral, Dose: 5 Milligram per animal, Frequency: 1 per day • Reactions: Erythema, Behavioral disorder (unspecified), Weight loss, Bumps on skin, Skin sore… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055886
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 6.623 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Dose: 5 Milligram per animal
  • Frequency: 1 per day
Reactions Reported:
Erythema Behavioral disorder (unspecified) Weight loss Bumps on skin Skin sore Decreased appetite Cyanotic spots/blotchy skin UNPALATABLE
Outcomes: Ongoing

Dog, Terrier - West Highland White, Male, 12 year, 9.52 kilogram • Drug: MSK, Suspension, Auricular (Otic), Dose: 1 dose per animal • Reactions: Deafness • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055789
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 9.520 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Auricular (Otic)
  • Form: Suspension
  • Dose: 1 dose per animal
Reactions Reported:
Deafness
Outcomes: Ongoing

Dog, Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog), Female, 2 year, 16.965 kilogram • Drug: MSK, Unknown • Reactions: Other abnormal test result NOS, Skin irritation, Skin inflammation NOS, Hives, Pustules • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-054907
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 2.00 Year
  • Weight: 16.965 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Other abnormal test result NOS Skin irritation Skin inflammation NOS Hives Pustules
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 8 year, 3.629 kilogram • Drug: MSK, Unknown, Dose: 0.50 mL per dose, Frequency: 24 per hour • Reactions: Oral bleeding, Haemorrhage NOS, Food refusal, Cardiac arrest, Death… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-055214
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 8.00 Year
  • Weight: 3.629 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Dose: 0.50 mL per dose
  • Frequency: 24 per hour
Reactions Reported:
Oral bleeding Haemorrhage NOS Food refusal Cardiac arrest Death Vocalisation Increased heart rate
Outcomes: Died

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.